Corneal Crosslinking Treatment Study

NCT04427956 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Progressive Keratoconus

Interventions

PROCEDURE: Corneal crosslinking: CXL (UVA 9mW/cm2)
DRUG: Isotonic riboflavin
DRUG: Hypotonic riboflavin
PROCEDURE: Iontophoresis

Sponsor

Region Skane